Prescription Justice president Gabriel Levitt joined @McGrawMilhaven on America at Night to discuss how a new CBP rule could disrupt Americans’ access to lower-cost prescription drugs imported for personal use. Listen here: https://t.co/et7p3rt5m6
Prescription Justice warns that a new CBP rule could make it harder for Americans to import affordable prescription medicines for personal use. FDA and CBP must protect patients while targeting unsafe drugs. Learn more:
https://t.co/FADdH2v6wT
Congress gave FDA direction on personal prescription drug importation >20 years ago. With millions of Americans unable to afford prescription drugs, it’s time to give § 804(j)(1) its due. New from PJ President Gabriel Levitt in @pennlaw@TheRegReview: https://t.co/9j49qDp7KS
🎉Big win for lower drug prices!
Prescription Justice congratulates #Colorado on receiving FDA approval for its Canadian wholesale prescription drug #importation program, now the 2nd state to move forward. Full statement: [https://t.co/rPjDwwQ7mW]
"Transparency reforms are popular as a bipartisan solution to mitigate drug costs, they do little for individual beneficiaries… it may also have the unintended consequence of ... pressuring competing PBMs to align their payment amounts to pharmacies" @AAF https://t.co/Um9RXujQH2
ICYMI: When the three #BigPharma giants who dominate the #insulin market were asked to rule out future #insulin price hikes, all three refused or caveated their answers to allow room to price-gouge patients in the future. Hold them accountable. @sanofi@novonordisk@EliLillyandCo
“PBMs help deliver savings to patients by negotiating the prices that pharmacies get reimbursed for prescription medicines. In addition, they frequently utilize contracting to help reduce costs,” – @taxreformer. More: https://t.co/LNbs5UYNae
“We urge the Senate to immediately act on legislation to lower drug prices through increased competition, transparency, and accountability.” Letter here → https://t.co/mtUfADMQSC
👎🏼The FDA and Big Pharma's new decision will hurt millions of Americans who are seeking to afford their life-saving medications. Here is a policy recommendation for the FDA based on Congress.
Pharmacy benefits save patients millions each year. Over the next decade, they’ll save government programs $445 billion. Tell lawmakers to halt legislation that will restrict pharmacy benefits: https://t.co/dFpn2Gnm4f
Big Pharma accumulates patents to protect their profits and keep more affordable generic and biosimilar competition off the market. Read @Alex_BrillDC’s report about the billion-dollar cost of Big Pharma’s tactics: https://t.co/B0Cn2955mo
Although insulin manufacturers are making steps in the right direction, lowered costs for some insulins are only quick fixes. They need to be held to account, with insulin prices controlled to ensure prices don't increase again. Click here for more info: https://t.co/o6XJDY56r4
Fact: PBMs’ interests are not aligned with lower drug prices.
“Higher prices put more dollars into a PBM’s pockets,” said professsor @ProfRobnFeldman.
Join us at https://t.co/MnYDxEDor5. We intend to win reforms that ensure PBMs serve patients.
https://t.co/yNuXMM0U8A
DYK: A recent poll found that more than 1/3 of patients couldn’t fill their #prescription medications because the price was too high. It’s time to hold #BigPharma accountable for their patent abuse that keeps #drugprices high.
Read the full report:
https://t.co/D4UhnJXmeV
The Problem With PBMs:
Abiraterone is generic, yet the average cost to Medicare per month is $3,000. Civica sells the drug for around $160, but try as they might, Civica cannot get PBMs to buy abiraterone.
PBMs prefer the higher price; patients pay.
https://t.co/JyEDq90cYC